MPM Bioimpact LLC Raises Stock Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

MPM Bioimpact LLC grew its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 34.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 230,000 shares of the company's stock after acquiring an additional 58,895 shares during the quarter. Janux Therapeutics comprises approximately 1.7% of MPM Bioimpact LLC's portfolio, making the stock its 28th biggest position. MPM Bioimpact LLC owned approximately 0.44% of Janux Therapeutics worth $12,314,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of JANX. Lester Murray Antman dba SimplyRich boosted its holdings in Janux Therapeutics by 205.3% in the fourth quarter. Lester Murray Antman dba SimplyRich now owns 24,315 shares of the company's stock worth $1,301,000 after purchasing an additional 16,351 shares during the last quarter. abrdn plc bought a new stake in shares of Janux Therapeutics during the 4th quarter valued at about $3,430,000. Barclays PLC grew its stake in shares of Janux Therapeutics by 496.5% during the 3rd quarter. Barclays PLC now owns 174,061 shares of the company's stock valued at $7,907,000 after purchasing an additional 144,883 shares during the period. Legal & General Group Plc grew its stake in shares of Janux Therapeutics by 45.3% during the 4th quarter. Legal & General Group Plc now owns 34,540 shares of the company's stock valued at $1,849,000 after purchasing an additional 10,776 shares during the period. Finally, Rhumbline Advisers grew its stake in shares of Janux Therapeutics by 1.6% during the 4th quarter. Rhumbline Advisers now owns 38,153 shares of the company's stock valued at $2,043,000 after purchasing an additional 599 shares during the period. 75.39% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Andrew Hollman Meyer sold 3,333 shares of the business's stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $32.03, for a total value of $106,755.99. Following the transaction, the insider now directly owns 82,139 shares of the company's stock, valued at approximately $2,630,912.17. The trade was a 3.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ra Capital Management, L.P. acquired 110,206 shares of the firm's stock in a transaction dated Friday, March 7th. The shares were purchased at an average cost of $31.02 per share, for a total transaction of $3,418,590.12. Following the completion of the acquisition, the director now directly owns 10,141,287 shares in the company, valued at approximately $314,582,722.74. This represents a 1.10% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have sold 10,001 shares of company stock valued at $313,964. Corporate insiders own 8.10% of the company's stock.

Analyst Ratings Changes

JANX has been the subject of a number of recent research reports. Wedbush restated an "outperform" rating and set a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. Scotiabank cut their price target on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a research note on Friday, February 28th. Finally, HC Wainwright restated a "buy" rating and set a $70.00 price target on shares of Janux Therapeutics in a research note on Monday, March 3rd. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, Janux Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $95.25.

Janux Therapeutics Price Performance

Shares of JANX stock traded down $0.27 on Monday, hitting $24.01. 362,004 shares of the stock traded hands, compared to its average volume of 867,007. The firm has a market cap of $1.42 billion, a price-to-earnings ratio of -20.52 and a beta of 3.24. Janux Therapeutics, Inc. has a 52 week low of $22.48 and a 52 week high of $71.71. The firm has a 50 day simple moving average of $28.66 and a two-hundred day simple moving average of $40.54.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, topping analysts' consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Sell-side analysts forecast that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.